Amprenavir is a protease inhibitor used to treat HIV infection. It was approved by
the Food and Drug Administration on April 15, 1999, for twice-a-day dosing ...
Easy to read patient leaflet for amprenavir. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Accession Number, DB00701 (APRD00605). Type, Small Molecule. Groups,
Approved. Description, Amprenavir is a protease inhibitor used to treat HIV
AIDS: The Food and Drug Administration (FDA) has approved amprenavir (
Agenerase, formerly known as 141W94 and VX-478) for treatment of HIV. The
drug is ...
AGENERASE (amprenavir) in combination with other antiretroviral agents is
indicated for ... contains 15 mg of amprenavir in solution and the inactive
Jan 25, 2001 ... Approval. Amprenavir was approved by the U.S. Food and Drug Administration (
FDA) in 1999 for use in adults and children with HIV infection.
Agenerase (amprenavir): For the treatment of HIV-1 infection.. New approved
drug details including side effects, uses and general information.
Manufacture of amprenavir was discontinued in October 2007. It is being
replaced by fosamprenavir (see fact sheet 448). Fosamprenavir is a pro-drug of ...
Sigma-Aldrich offers Sigma-SML0685, Amprenavir for your research needs. Find
product specific information including CAS, MSDS, protocols and references.
ABSTRACT. Amprenavir (141W94) is extensively metabolized by P450
cytochromes, specifically, CYP3A4. Because hepatic insufficiency reduces ...